Background: KPC-type carbapenemases are increasingly prevalent in parts of the USA and Israel and are an emerging concern in South America, Europe and China. We investigated the UK's first two KPC-producing Klebsiella pneumoniae isolates.
Introduction
The global explosion of CTX-M-type extended-spectrum b-lactamases and, to a lesser extent, acquired AmpC enzymes in clinical isolates of Escherichia coli and Klebsiella spp. drives therapeutic choice increasingly towards carbapenems. For this reason, carbapenem-hydrolysing b-lactamases (carbapenemases) represent a serious public health threat.
Carbapenemases are diverse, including representatives of b-lactamase molecular classes A, B (metalloenzymes) and D (OXA enzymes). Class A carbapenemases are generally rare, but the KPC (Klebsiella pneumoniae carbapenemase) variants are now spreading rapidly. There are currently six recognized variants (note that KPC-1 is synonymous with KPC-2), with KPC-2 and KPC-3 most frequently reported. K. pneumoniae is their usual host, but bla KPC genes have spread to other members of the Enterobacteriaceae and, in Colombia, have been described in Pseudomonas spp. 1 Isolates with KPC enzymes are increasingly prevalent in many parts of the USA, particularly in New York. 2, 3 Beyond the USA, there have been hospital outbreaks of infection caused by KPC-producing isolates in Israel, 4, 5 and producers are an emerging public health concern in Europe, 6,7 China 8,9 and Central and South America. 10 We report here the characterization of the UK's first K. pneumoniae isolates producing KPC enzymes.
Materials and methods

Bacterial isolates
The first K. pneumoniae was isolated, at admission, in 2007 from blood cultures of an elderly male in a Scottish hospital (hospital A); he had no history of foreign travel in the preceding 6 years, but had been hospitalized elsewhere in Scotland. The second isolate was from London (hospital B) in 2008, from a urine specimen of an elderly female renal transplant patient; her recent history included admission into a hospital in Israel (city and hospital unknown), 1 month prior to isolation of the bacterium, for the treatment of pyelonephritis. Both K. pneumoniae isolates were referred to the HPA's Antibiotic Resistance Monitoring and Reference Laboratory for confirmation of carbapenem resistance.
Further isolates of K. pneumoniae, representing a strain responsible for a hospital outbreak in Bnei Brak, Israel, were recovered from storage at 2708C.
Antibiotic susceptibility testing and strain typing
Susceptibilities were determined by BSAC agar dilution methodology or Etest (AB Biodisk, Solna, Sweden) and interpreted using European Committee for Antimicrobial Susceptibility Testing (EUCAST)/BSAC (v.7) breakpoints.
Isolates were compared by PFGE, initially using XbaI-digested genomic DNA, and then with SpeI-digested DNA. 5, 11 BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) was used to determine relatedness with other referred K. pneumoniae isolates.
Characterization of bla KPC and Tn4401-like elements
Isolates were screened for bla KPC using primers 5 0 -TGT CAC TGT ATC GCC GTC-3 0 and 5 0 -CTC AGT GCT CTA CAG AAA ACC-3 0 , 2,3 and the amplicons were sequenced using dye-terminator chemistry on a CEQ8000 Genetic Analyser (Beckman-Coulter, High Wycombe, UK). Sequences were compared and aligned with reference sequences using BLAST (http://blast.ncbi.nlm.nih.gov/ Blast.cgi) and CLUSTAL W (http://www.ebi.ac.uk/clustalw). Location of the bla KPC genes within Tn4401-like elements was investigated using the six primer pairs described by Naas et al.
12
K. pneumoniae isolate CL-5761 (KPC-3) 3 and Enterobacter sp. isolate E624 (KPC-4, GenBank no. AY700571) were used as positive controls for PCR assays.
In addition, a bla OXA-9-like allele was sought with primers 5 0 -GCT GCA TAT GTT GGT GTT CG-3 0 and 5 0 -TTG CTC CTT GGG AGA TAT GG-3 0 (expected product size 480 bp). Linkage of this allele with bla TEM-1 , as found on Tn1331, 13, 14 was sought with primers 5 0 -GGG TCT AAA GCA CGA GAG GA-3 0 (located at the 3 0 end of bla OXA-9 ) and 5 0 -AGC AAA AAC AGG AAG GCA AA-3 0 (located at the 5 0 end of bla TEM-1 ; expected product size 828 bp).
Results and discussion
The two K. pneumoniae isolates were referred, 5 months apart, from different UK hospitals (one in Scotland and the other in London), with no discernible connections between the cases. Carbapenem resistance was recognized by the sending laboratories and was subsequently confirmed for all analogues by MIC determination (MICs . 16 mg/L; Table 1 ). Imipenem MICs were unchanged by EDTA, which ruled out production of a class B metallo-carbapenemase. The isolates were resistant to all other b-lactams tested, including combinations with clavulanic acid and cloxacillin, which are inhibitors of class A and C b-lactamases, respectively. They were resistant to tobramycin, amikacin and ciprofloxacin, showed susceptibility or intermediate susceptibility to tigecycline (MICs 1 -2 mg/L) and retained susceptibility only to gentamicin (MICs 0.5 -1 mg/L) and colistin (MICs 0.5 mg/L). A bla KPC allele was detected by PCR in both of the isolates, and PFGE of XbaI-digested DNA revealed that they belonged to the same strain. Comparison with other K. pneumoniae in our database revealed high relatedness (.85% banding pattern similarity) to a cluster of KPC-producing isolates received in 2007 from a hospital outbreak in Bnei Brak, Israel; no other closely related isolates were identified.
Since KPC-producing K. pneumoniae strains with similar antibiograms (susceptibility only to gentamicin and colistin) have been reported previously in Tel Aviv, Israel, 5 we sought also to compare the UK and Bnei Brak isolates with the most widely disseminated Tel Aviv strain, designated clone Q. 5 We compared the banding patterns of SpeI digests with an electronic gel image of SpeI-digested DNA from clone Q (an isolate of the Tel Aviv clone was not available for testing in parallel). The profiles were indistinguishable (Figure 1 ): both the UK and the Bnei Brak isolates belonged to Tel Aviv clone Q.
Consistent with the reported characteristics of clone Q, 5 both the UK and the representative Bnei Brak isolates were shown by sequencing to produce KPC-3 carbapenemase, a variant with a His-272!Tyr substitution first reported in New York. 3 Further PCR analyses confirmed that their bla KPC genes were flanked by upstream and downstream copies of ISKpn7 and ISKpn6, respectively, located within larger Tn4401-like elements (approx. 10 kb). 12 All of the isolates also harboured a bla OXA-9-like allele linked to bla TEM-1 , as found on Tn1331, 14 and associated previously with bla KPC-3 . 13 In summary, the first two K. pneumoniae isolates with KPC carbapenemase detected in the UK represented a single strain, although there were no discernible epidemiological connections between the cases. Furthermore, this strain was indistinguishable from a KPC-3-producing strain currently circulating in Israel, both in Tel Aviv, 5 and elsewhere (as demonstrated in this study). An 'Israel connection' was consistent with the history of the London (hospital B) patient, suggesting that particular isolate was probably imported into the UK. However, we cannot exclude the possibility that this KPC-positive strain may be circulating more widely outside Israel, since the provenance of the Scottish (hospital A) isolate remains unclear, with no links established to other countries. K. pneumoniae with KPC carbapenemases were originally isolated in the USA 2,3 and, besides Israel, have also been reported in China, 8, 9 France 6 and Greece. 7 Given the limited therapeutic options available for infections caused by these multiresistant K. pneumoniae strains, there is an urgent need to compare producer isolates from different countries to monitor the potential international dissemination of resistant clones.
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